PROTALIX BIOTHERAPEUTICS INC (PLX)

US74365A3095 - Common Stock

1.26  +0.01 (+0.8%)

After market: 1.26 0 (0%)

Fundamental Rating

6

Taking everything into account, PLX scores 6 out of 10 in our fundamental rating. PLX was compared to 592 industry peers in the Biotechnology industry. Both the profitability and the financial health of PLX get a neutral evaluation. Nothing too spectacular is happening here. PLX is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make PLX a good candidate for growth investing.



6

1. Profitability

1.1 Basic Checks

PLX had positive earnings in the past year.
PLX had a negative operating cash flow in the past year.
PLX had negative earnings in 4 of the past 5 years.
PLX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of PLX (9.85%) is better than 97.45% of its industry peers.
The Return On Equity of PLX (24.77%) is better than 97.96% of its industry peers.
The Return On Invested Capital of PLX (21.24%) is better than 99.49% of its industry peers.
Industry RankSector Rank
ROA 9.85%
ROE 24.77%
ROIC 21.24%
ROA(3y)-18.11%
ROA(5y)-20.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 12.69%, PLX belongs to the best of the industry, outperforming 96.60% of the companies in the same industry.
Looking at the Operating Margin, with a value of 15.97%, PLX belongs to the top of the industry, outperforming 96.43% of the companies in the same industry.
In the last couple of years the Operating Margin of PLX has grown nicely.
Looking at the Gross Margin, with a value of 64.90%, PLX belongs to the top of the industry, outperforming 81.97% of the companies in the same industry.
PLX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 15.97%
PM (TTM) 12.69%
GM 64.9%
OM growth 3Y54.76%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.76%
GM growth 5Y-2.28%

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PLX is creating value.
PLX has more shares outstanding than it did 1 year ago.
PLX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PLX has an improved debt to assets ratio.

2.2 Solvency

PLX has an Altman-Z score of -3.72. This is a bad value and indicates that PLX is not financially healthy and even has some risk of bankruptcy.
PLX has a Altman-Z score of -3.72. This is in the lower half of the industry: PLX underperforms 60.71% of its industry peers.
There is no outstanding debt for PLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.72
ROIC/WACC2.18
WACC9.76%

2.3 Liquidity

PLX has a Current Ratio of 1.54. This is a normal value and indicates that PLX is financially healthy and should not expect problems in meeting its short term obligations.
PLX's Current ratio of 1.54 is on the low side compared to the rest of the industry. PLX is outperformed by 84.01% of its industry peers.
A Quick Ratio of 1.12 indicates that PLX should not have too much problems paying its short term obligations.
PLX has a Quick ratio of 1.12. This is amonst the worse of the industry: PLX underperforms 87.24% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.12

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 116.67% over the past year.
The Revenue has grown by 37.49% in the past year. This is a very strong growth!
The Revenue has been growing by 13.85% on average over the past years. This is quite good.
EPS 1Y (TTM)116.67%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q0%
Revenue 1Y (TTM)37.49%
Revenue growth 3Y1.36%
Revenue growth 5Y13.85%
Revenue growth Q2Q21.65%

3.2 Future

Based on estimates for the next years, PLX will show a very strong growth in Earnings Per Share. The EPS will grow by 304.50% on average per year.
PLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 41.08% yearly.
EPS Next Y192.9%
EPS Next 2Y304.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-2.89%
Revenue Next 2Y41.08%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 25.20, which means the current valuation is very expensive for PLX.
Based on the Price/Earnings ratio, PLX is valued cheaply inside the industry as 96.09% of the companies are valued more expensively.
PLX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.48.
With a Price/Forward Earnings ratio of 8.60, the valuation of PLX can be described as very reasonable.
99.15% of the companies in the same industry are more expensive than PLX, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of PLX to the average of the S&P500 Index (22.79), we can say PLX is valued rather cheaply.
Industry RankSector Rank
PE 25.2
Fwd PE 8.6

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PLX is valued cheaper than 97.96% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.54

4.3 Compensation for Growth

PLX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of PLX may justify a higher PE ratio.
A more expensive valuation may be justified as PLX's earnings are expected to grow with 304.50% in the coming years.
PEG (NY)0.13
PEG (5Y)N/A
EPS Next 2Y304.5%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for PLX!.
Industry RankSector Rank
Dividend Yield N/A

PROTALIX BIOTHERAPEUTICS INC

NYSEARCA:PLX (3/28/2024, 8:04:01 PM)

After market: 1.26 0 (0%)

1.26

+0.01 (+0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap91.92M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 25.2
Fwd PE 8.6
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.13
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 9.85%
ROE 24.77%
ROCE
ROIC
ROICexc
ROICexgc
OM 15.97%
PM (TTM) 12.69%
GM 64.9%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.54
Quick Ratio 1.12
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)116.67%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y192.9%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)37.49%
Revenue growth 3Y1.36%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y